EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model

• Main Authors: Xiaokun Yang, Yadong Yang, Shuqian Tang, Hui Tang, Guihong Yang, Qiaoyu Xu, Jinjin Wu
• Format: Article
• Language: English
• Published: Elsevier 2015-09-01
• Series: Journal of Pharmacological Sciences
• Subjects: Cisplatin; A375; EphB4; Melanoma
• Online Access: http://www.sciencedirect.com/science/article/pii/S1347861315001929

The purpose of this paper is to investigate the possible mechanisms of resistance to chemotherapy in melanoma from the perspective of molecular biology and to discuss the strategies to overcome them. Cisplatin, a DNA-damaging compound that triggers apoptotic cell death, is commonly used in the treatment of malignant melanoma. However, most patients develop mechanisms of acquired resistance and about 25% of them do not achieve tumor regression at all, due to intrinsic resistance to therapy. In the current study, we reported the tumor xenografts of the human A375 melanoma, after 40-weeks’ consecutive therapy with cisplatin that developed resistance as a result of EphB4 overexpression. Moreover, the expression of phospho-AKT and phospho-ERK were significantly increased in cisplatin-resistant tumors. In addition, combined of cisplatin with EphB4 selective inhibitor could abrogate this acquired mechanism of drug resistance due to an enhanced apoptotic effect in cisplatin-resistant xenografts. In summary, these results help to understand the mechanisms of acquired resistance to chemotherapy and provide important information for clinical treatment strategies.